Fuso Pharmaceutical Industries,Ltd. (JP:4538)
:4538
Want to see JP:4538 full AI Analyst Report?
Top Page
Fuso Pharmaceutical Industries,Ltd.
(4538)
Select Model
Select Model
Rating:52Neutral
Price Target:
¥2,032.00
▼(-12.22% Downside)
Action:Reiterated
Date:05/14/26
The score is held back primarily by weak cash flow and rising leverage, alongside bearish technicals with the stock trading below key moving averages. A low P/E and high dividend yield provide valuation support, but do not fully offset the near-term financial quality and momentum risks.
Positive Factors
Specialized injectable focus
A clear specialization in injectables and infusion therapies indicates deep manufacturing know‑how, regulatory expertise and high barriers to entry in hospital channels. This niche focus supports stable institutional demand, long product life cycles and repeat hospital contracts over months to years.
Negative Factors
Deteriorated cash generation
A sustained swing to negative operating and free cash flow in FY2025–FY2026 materially weakens financial resilience. Negative cash conversion constrains capex and working capital funding, raises refinancing needs and makes the business more vulnerable to profit or demand shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized injectable focus
A clear specialization in injectables and infusion therapies indicates deep manufacturing know‑how, regulatory expertise and high barriers to entry in hospital channels. This niche focus supports stable institutional demand, long product life cycles and repeat hospital contracts over months to years.
Read all positive factors
Fuso Pharmaceutical Industries,Ltd. (4538) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥18.26B
Dividend Yield3.71%
Average Volume (3M)17.49K
Price to Earnings (P/E)8.7
Beta (1Y)0.61
Revenue Growth2.88%
EPS GrowthN/A
CountryJP
Employees1,370
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)54.10
Shares Outstanding9,451,169
10 Day Avg. Volume18,340
30 Day Avg. Volume17,486
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.58
Price to Sales (P/S)0.32
P/FCF Ratio-2.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Fuso Pharmaceutical Industries,Ltd. Business Overview & Revenue Model
Company Description
Fuso Pharmaceutical Industries, Ltd. is a Japanese firm primarily involved in the development and commercialization of pharmaceutical goods. Their product range encompasses prescription medications, particularly injectables and solutions for artif...
How the Company Makes Money
null...
Fuso Pharmaceutical Industries,Ltd. Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
58
Neutral
Cash Flow
29
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.50B | 62.31B | 60.56B | 55.41B | 51.02B | 49.63B |
| Gross Profit | 4.08B | 15.99B | 16.19B | 13.52B | 13.36B | 12.91B |
| EBITDA | 1.36B | 5.38B | -2.98B | 3.67B | 4.63B | 4.47B |
| Net Income | 462.00M | 2.01B | -3.29B | 1.38B | 1.60B | 1.48B |
Balance Sheet | ||||||
| Total Assets | 86.99B | 90.32B | 82.52B | 76.46B | 72.81B | 69.66B |
| Cash, Cash Equivalents and Short-Term Investments | 3.16B | 4.85B | 6.26B | 5.12B | 8.01B | 7.35B |
| Total Debt | 28.23B | 28.46B | 21.29B | 12.72B | 11.41B | 12.09B |
| Total Liabilities | 53.81B | 55.26B | 49.48B | 39.79B | 37.15B | 35.12B |
| Stockholders Equity | 33.18B | 35.06B | 33.04B | 36.66B | 35.65B | 34.53B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -7.49B | -5.43B | -2.62B | 1.32B | 2.20B |
| Operating Cash Flow | 0.00 | -6.22B | -3.31B | 627.00M | 2.87B | 3.61B |
| Investing Cash Flow | 0.00 | -1.51B | -3.17B | -3.54B | -1.39B | -1.66B |
| Financing Cash Flow | 0.00 | 6.32B | 7.62B | 14.00M | -813.00M | -1.67B |
Fuso Pharmaceutical Industries,Ltd. Technical Analysis
Neutral
2315.00
Price Trends
2138.36
Negative
2242.95
Negative
2199.79
Negative
Market Momentum
-18.87
Negative
52.56
Neutral
63.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4538, the sentiment is Neutral. The current price of 2315 is above the 20-day moving average (MA) of 2038.25, above the 50-day MA of 2138.36, and above the 200-day MA of 2199.79, indicating a neutral trend. The MACD of -18.87 indicates Negative momentum. The RSI at 52.56 is Neutral, neither overbought nor oversold. The STOCH value of 63.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4538.
Fuso Pharmaceutical Industries,Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥13.22B | 25.13 | ― | ― | 1.62% | -25.43% | |
63 Neutral | ¥8.77B | 14.02 | ― | 2.55% | -0.61% | 14.60% | |
53 Neutral | ¥8.92B | 39.26 | ― | 1.06% | 27.18% | 252.59% | |
52 Neutral | ¥18.26B | 8.74 | ― | 3.71% | 2.88% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥15.56B | 36.14 | ― | 3.65% | 8.42% | 49.52% | |
50 Neutral | ¥5.49B | 28.72 | ― | 3.21% | 1.60% | -32.57% |
* Healthcare Sector Average
JP:4538
Fuso Pharmaceutical Industries,Ltd.
2,082.00
76.76
3.83%
JP:2929
Pharma Foods International Co., Ltd.
537.00
-303.51
-36.11%
JP:4512
Wakamoto Pharmaceutical Co., Ltd.
257.00
-46.44
-15.31%
JP:4524
Morishita Jintan Co., Ltd.
2,151.00
91.09
4.42%
JP:4539
Nippon Chemiphar Co., Ltd.
1,520.00
45.00
3.05%
JP:4574
Taiko Pharmaceutical Co., Ltd.
264.00
-95.00
-26.46%
Fuso Pharmaceutical Industries,Ltd. Corporate Events
Fuso Pharmaceutical Reshapes Production Leadership With Director Retirement and Executive Promotion
May 12, 2026
Fuso Pharmaceutical Industries, Ltd. announced board-level personnel changes following a May 12, 2026 directors’ meeting, marking a planned transition in its production leadership. Director and Production Division General Manager Jun-ichi Ok...
Fuso Pharmaceutical Lifts Dividend as Profit Falls Despite Higher Sales
May 12, 2026
Fuso Pharmaceutical Industries reported a 2.9% increase in net sales to ¥62.3 billion for the year ended March 31, 2026, but operating and ordinary profits fell 36.1% and 37.9%, respectively, as margins contracted. Despite this, the company s...
Fuso Pharmaceutical Secures ¥13.4 Billion Syndicated Loan to Expand Dialysis Production
Mar 31, 2026
Fuso Pharmaceutical Industries has signed a ¥13.4 billion syndicated commitment-type term loan arranged by Sumitomo Mitsui Banking Corporation to finance its key manufacturing expansion plan. The funds will support construction of a second fo...
Fuso Pharmaceutical Profit Slumps Despite Modest Sales Growth
Feb 17, 2026
Fuso Pharmaceutical Industries reported non-consolidated net sales of ¥48.27 billion for the nine months ended December 31, 2025, up 3.4% year on year, but operating profit dropped 34.8% to ¥2.37 billion and ordinary profit fell 33.7%, w...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.